AN2 Therapeutics (ANTX) 2025 Annual Report – Key Highlights for Investors

1. Company Overview

AN2 Therapeutics, Inc. (Nasdaq: ANTX) is a clinical-stage biopharmaceutical company focused on the development of boron-based small molecule therapeutics for infectious diseases. The company is incorporated in Delaware and headquartered in Menlo Park, California.

2. Key Financial and Corporate Status Highlights

• Public Float: As of June 30, 2025, the aggregate market value of shares held by non-affiliates was \$23,078,812, based on the Nasdaq closing price. There were 35,941,195 shares of common stock outstanding as of March 10, 2026.
• Listing: AN2 Therapeutics’ common stock trades on the Nasdaq Global Select Market under the symbol ANTX.
• Filing Status: The company is a “smaller reporting company” and an “emerging growth company” as defined under SEC regulations, which may allow for reduced disclosure requirements and could impact investor expectations regarding governance and transparency.
• Internal Controls: The company’s independent auditor did not provide an attestation report on internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act, which is typical for an emerging growth company.

3. Forward-Looking Statements

The report contains numerous forward-looking statements, including projections about future operations, business strategies, product candidates, clinical trial plans, regulatory milestones, and funding needs. These statements are subject to uncertainties and risks, including factors outside the company’s control, which could materially impact future performance.

• Key forward-looking areas include:
  • The timing, progress, and outcomes of preclinical and clinical studies, including manufacturing for clinical and commercial supply.
  • The sufficiency of current cash to fund operating expenses and capital expenditures.
  • Plans to leverage non-dilutive funding such as government grants, contracts, and partnerships to support global health programs.
  • Regulatory approval strategies and anticipated milestones for the company’s boron-based therapeutics.
  • Potential impact of macroeconomic factors and geopolitical risks on business operations and supply chains.
  • The period during which AN2 expects to qualify as an “emerging growth company” under the JOBS Act.

4. Strategic and Operational Highlights

• Pipeline Progress: AN2’s lead boron-based assets are progressing through Phase 2 and into later-stage studies. The company is focused on demonstrating safety, efficacy, and a clear development path towards potential registration.
• Manufacturing: AN2 does not own or operate manufacturing facilities, instead relying on third-party contract manufacturers for clinical trial material and eventual commercialization. This could introduce risks related to supply chain reliability and cost structures.
• Non-Dilutive Funding: The company is actively pursuing and utilizing non-dilutive capital, such as grants and government contracts, aimed at advancing its global health programs. This approach can reduce the need for dilutive equity offerings, which is positive for existing shareholders.
• Intellectual Property and Trade Secrets: AN2 relies on patents, trade secrets, know-how, and confidentiality agreements to protect its proprietary technology. While best efforts are made to protect IP, trade secrets can be difficult to enforce, and there’s no guarantee all proprietary information is adequately protected.
• Regulatory and Compliance Risks: The company highlights substantial regulatory hurdles and the risk of FDA or other regulatory actions, including product holds, fines, or even complete withdrawal from the market. The regulatory landscape for anti-infective products is complex and could impact time-to-market or commercial success.
• Sunshine Act and Compliance: The company is subject to federal and state reporting requirements under the Physician Payments Sunshine Act, which mandates disclosure of certain payments to physicians and teaching hospitals. There are also state and local laws affecting business practices in the pharmaceutical industry.

5. Risks and Shareholder Considerations

• Business and Industry Risks: The company’s future success is highly dependent on successful clinical development, regulatory approval, and commercialization of its pipeline assets. Any delays, failures, or regulatory setbacks could significantly impact share value.
• Funding Needs: While the company is focused on non-dilutive funding, ongoing R&D and clinical activities may require additional financing, which could be dilutive to existing shareholders.
• Market Factors: The company’s financial performance and share price may be affected by industry competition, inflation, macroeconomic trends, and geopolitical events impacting the biotechnology sector.
• Proxy Statement Reference: Portions of the company’s definitive 2025 annual proxy statement are incorporated by reference into this report for information on executive compensation, security ownership, and governance.

6. Table of Contents – Key Sections for Investors

• Item 1: Business Overview
• Item 1A: Risk Factors
• Item 1C: Cybersecurity
• Item 7: Management’s Discussion and Analysis of Financial Condition and Results of Operations
• Item 8: Financial Statements and Supplementary Data
• Item 12: Security Ownership of Certain Beneficial Owners and Management

7. Potential Price-Sensitive Information for Shareholders

• Clinical Pipeline Progress: The advancement of boron-based assets into later-stage trials could serve as a major catalyst for share price movement, especially on positive efficacy or safety data.
• Non-Dilutive Funding: Continued success in securing government grants and partnerships can preserve shareholder value by reducing dilution risk.
• Emerging Growth Company Status: The company’s status as an emerging growth and smaller reporting company means it may benefit from less burdensome regulations, but may also face increased volatility and risk perceptions by investors.
• Regulatory Risks: Any significant regulatory changes, delays, or adverse findings during inspections or reviews could negatively impact the share price.
• Market Value and Float: With a relatively modest public float and market cap, the stock could be more volatile, and significant news—positive or negative—could have outsized impacts on trading.

Disclaimer

This article is based on the 2025 Annual Report of AN2 Therapeutics, Inc. It contains forward-looking statements and interpretations intended for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence, consider all risk factors, and consult with financial professionals before making investment decisions. The company’s future performance is subject to significant uncertainties and risks as outlined above.

View AN2 Therapeutics, Inc. Historical chart here